Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Lymphoma

Free Subscription Articles published in Neurology Retrieve available abstracts of 14 articles: HTML format

Single Articles

June 2024
1. MOHEB N, Tobin WO, Olsen TW, Chen JJ, et al
   Teaching NeuroImage: Fundoscopic and Optical Coherence Tomography Changes in Primary CNS Lymphoma.
   Neurology. 2024;102:e209512.
   PubMed    
   
   
   March 2024
2. LI CMF, MacDougall K, Fraser JA
   Teaching NeuroImage: Transcalvarial Lymphoma: A Rare Cause of Secondary Intracranial Hypertension.
   Neurology. 2024;102:e209227.
   PubMed    
   
   
   August 2023
3. GRIFFIN KJ, Toledano M, Flanagan EP, Mustafa R, et al
   "Trident Sign" in Primary CNS B-Cell Spinal Cord Lymphoma.
   Neurology. 2023 Aug 30:10.1212/WNL.0000000000207671.
   PubMed    
   
   
   
4. RATTANAWONG W, Tekarjnavanit A, Marukatat C, Hemachudha P, et al
   Teaching NeuroImage: Branching Dura Mater in Primary Central Nervous System, ALK-Positive, Anaplastic Large Cell Lymphoma.
   Neurology. 2023 Aug 3:10.1212/WNL.0000000000207752.
   PubMed    
   
   
   
5. KARSCHNIA P, Kurz SC, Brastianos PK, Winter SF, et al
   Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Primary CNS Lymphoma Patients Treated With Methotrexate-Based Regimens.
   Neurology. 2023 Aug 1:10.1212/WNL.0000000000207670.
   PubMed     Abstract available
   
   
   June 2023
6. THERKELSEN KE, Schaff LR, Nandakumar S, Omuro AMP, et al
   Long-term Outcomes in Primary CNS Lymphoma Following R-MVP and High Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.
   Neurology. 2023 Jun 21:10.1212/WNL.0000000000207490.
   PubMed     Abstract available
   
   
   May 2023
7. 
   Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
   Neurology. 2023 May 3:10.1212/WNL.0000000000207470.
   PubMed    
   
   
   April 2023
8. KARSCHNIA P, Rejeski K, Subklewe M, von Baumgarten L, et al
   Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
   Neurology. 2023;100:687-688.
   PubMed    
   
   
   
9. LEWIS A, Galetta S
   Editors' Note: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
   Neurology. 2023;100:687.
   PubMed    
   
   
   
10. TAN BJ, Chan LL, Tan EK
    Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Neurology. 2023;100:688.
    PubMed    
    
    
    March 2023
11. LU L, Zhu A, Itoh CY, Coburn RP, et al
    CNS T-Cell Lymphoma Many Years After Hemophagocytic Lymphohistiocytosis.
    Neurology. 2023 Mar 28:10.1212/WNL.0000000000207244.
    PubMed    
    
    
    July 2022
12. URSU R, Maillet D, Belin C, Moroni C, et al
    Long-Term Neurological Safety in B-Cell Lymphoma Patients Treated With Anti-CD19 CAR T-Cell Therapy.
    Neurology. 2022 Jul 18. pii: WNL.0000000000201083.
    PubMed     Abstract available
    
    
    March 2022
13. KARSCHNIA P, Rejeski K, Winkelmann M, Schoberl F, et al
    Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
    Neurology. 2022 Mar 29. pii: WNL.0000000000200608.
    PubMed     Abstract available
    
    
    September 2021
14. HOUILLIER C, Chabrot CM, Moles-Moreau MP, Willems L, et al
    Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.
    Neurology. 2021;97:628-631.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.